Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-12

Clinical Trial Update: Post-transplant Flotetuzumab for AML [Phase 1]

View source ↗

Summary

Phase 1 results update for flotetuzumab in post-transplant acute myeloid leukemia. Results were posted on 2025-09-12.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flotetuzumab (flotetuzumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED | Results posted: 2025-09-12